25 March 2021 in Nature Structural & Molecular Biology
8 March 2017 in Scientific Reports
Misfolded prion protein aggregates (PrPSc) show remarkable structural diversity and are associated with highly variable disease phenotypes. Similarly, other proteins, including amyloid-β, tau, α-synuclein, and serum amyloid A, misfold into distinct conformers linked to different clinical diseases through poorly understood mechanisms. Here we use mice expressing glycophosphatidylinositol (GPI)-anchorless prion protein, PrPC, together with hydrogen-deuterium exchange coupled with mass spectrometry (HXMS) and a battery of biochemical and biophysical tools to investigate how post-translational modifications impact the aggregated prion protein properties and disease phenotype. Four GPI-anchorless prion strains caused a nearly identical clinical and pathological disease phenotype, yet maintained their structural diversity in the anchorless state. HXMS studies revealed that GPI-anchorless PrPSc is characterized by substantially higher protection against hydrogen/deuterium exchange in the C-terminal region near the N-glycan sites, suggesting this region had become more ordered in the anchorless state. For one strain, passage of GPI-anchorless prions into wild type mice led to the emergence of a novel strain with a unique biochemical and phenotypic signature. For the new strain, histidine hydrogen-deuterium mass spectrometry revealed altered packing arrangements of β-sheets that encompass residues 139 and 186 of PrPSc. These findings show how variation in post-translational modifications may explain the emergence of new protein conformations in vivo and also provide a basis for understanding how the misfolded protein structure impacts the disease.
2 September 2026 in Journal of AOAC INTERNATIONAL
Background: Transmissible spongiform encephalopathy (TSE) agents are lethal unconventional pathogens that have infected both humans and animals. Bovine spongiform encephalopathy (BSE) is a TSE. TSE agents are unusually resistant to inactivation. In-use tests conducted to investigate decontamination products involve intentionally contaminating carrier objects with TSE agents, exposing them to decontaminating regimens, and then surgically implanting treated carriers into TSE-susceptible rodents to assay for TSE infectivity. Objective: To adapt a simple in-use carrier test to decontaminate TSE agents based on methods employed for decades to test for bacteria, fungi, and viruses remaining on surfaces treated with disinfectants, known as “use-dilution tests.” Methods: We serially diluted 10% BSE brain homogenate in a normal bovine-brain-tissue paste and contaminated 60 stainless-steel pins mounted in disposable heat-resistant plastic holders with the lowest dilution and five or six pins with each successive dilution. We investigated 2 N NaOH—known to inactivate TSE agents—with and without autoclaving (121°C and 134°C) and autoclaving without exposure to NaOH. Each pin was briefly introduced into the brain of an anesthetized mouse. We monitored animals for 24 months. At the end of the study, the brains of all mice (except six mice that died early post-inoculation) were tested for the presence of abnormal prion protein, a marker of TSE infections. Next, we calculated the level of inactivation provided by each method. Results: Our results indicated that none of the 60 animals inoculated with pins decontaminated with NaOH (with or without autoclaving) developed BSE, while steam autoclaving alone at both conventional and elevated temperatures was not effective. This inactivation corresponded to ≥1.1 log10 reduction of infectivity. Conclusions: Using our relatively simple and quick pin method with brief intracerebral punctures without surgical implantation, we tested many more replicate treated carriers than in studies previously reported while yielding similar results. Highlights: The proposed pin method was proven effective to evaluate inactivation regimens for BSE agents.